Therefore, it is an ideal strategy to target cancerous FN for metastatic prevention, whereas therapeutics targeting activated fibroblasts in TMEs may be concomitantly used to prevent tumor growth due to loss of FN expression. The gene discussed is FN1; the disease is neoplasm.